S
Soumya Swaminathan
Researcher at Indian Council of Medical Research
Publications - 370
Citations - 78067
Soumya Swaminathan is an academic researcher from Indian Council of Medical Research. The author has contributed to research in topics: Tuberculosis & Population. The author has an hindex of 69, co-authored 353 publications receiving 61963 citations. Previous affiliations of Soumya Swaminathan include Yahoo! & Ministry of Health and Family Welfare.
Papers
More filters
Journal ArticleDOI
Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India.
Dina Nair,Banurekha Velayutham,T Kannan,Jaya Prasad Tripathy,Anthony D. Harries,Mohan Natrajan,Soumya Swaminathan +6 more
TL;DR: Long delays from sputum collection to treatment initiation using conventional methods, along with poor treatment outcomes, suggest the need to scale up rapid diagnostic tests and shorter regimens for MDR-TB.
Journal ArticleDOI
Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial.
Narendran Gopalan,Ramesh Kumar Santhanakrishnan,Alangudi Natarajan Palaniappan,Pradeep A. Menon,Sekar Lakshman,Padmapriyadarsini Chandrasekaran,Gomathi Sivaramakrishnan,Devarajulu Reddy,Bhavani Perumal Kannabiran,Hemanth Kumar Kupparam Agiboth,Vijay Krishnamoorthy,Sridhar Rathinam,Chandrasekar Chockalingam,Tamizhselvan Manoharan,Mahilmaran Ayyamperumal,Nalini Jayanthi,Kumar Satagopan,Ravichandran Narayanan,Raja Krishnaraja,Sekar Sathiyavelu,Bhanu Kesavamurthy,Chandra Suresh,Murugesan Selvachitiram,Gunasundari Arasan,Stella Susaimuthu,Prabhakaran Rathinam,Prabhakar Angamuthu,Lavanya Jayabal,Lakshmi Murali,Ranjani Ramachandran,Srikanth Tripathy,Soumya Swaminathan +31 more
TL;DR: Among HIV-positive patients with pulmonary TB receiving antiretroviral therapy, a daily anti-TB regimen proved superior to a thrice-weekly regimen in terms of efficacy and emergence of rifampicin resistance.
Journal ArticleDOI
Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
Geetha Ramachandran,A K Hemanth Kumar,T. Kannan,P. K. Bhavani,S. Ramesh Kumar,N. Poorana Gangadevi,V. V. Banurekha,Vasudevan Sudha,Sushma Venkatesh,Narayanan Ravichandran,S. Kalpana,G. Mathevan,G. N. Sanjeeva,Dipti Agarwal,Soumya Swaminathan +14 more
TL;DR: HIV infection was associated with lower Cmax of R MP and INH and AUC0-8 of RMP and the need to increase anti-TB drug doses in children with HIV and TB is suggested.
Journal Article
Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy
Soumya Swaminathan,C N Deivanayagam,S. Rajasekaran,Perumal Venkatesan,Chandrasekaran Padmapriyadarsini,Pradeep A. Menon,C Ponnuraja,Meenalochani Dilip +7 more
TL;DR: Though the early bacteriological response to intermittent short course antituberculosis regimen was satisfactory, the overall outcome was adversely affected by the high mortality (during and after completion of treatment) and recurrence rate among HIV-infected patients with tuberculosis.
Journal ArticleDOI
Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.
Shashikant Srivastava,Devyani Deshpande,Jotam G. Pasipanodya,Eric L. Nuermberger,Soumya Swaminathan,Tawanda Gumbo +5 more
TL;DR: The regimen and doses of linezolid, moxifloxacin, and faropenem identified are proposed to be adequate for all disseminated tuberculosis syndromes, whether drug-resistant or -susceptible.